Residual daytime sleepiness in obstructive sleep apnea after continuous positive airway pressure optimization: causes and management

Julia L. Chapman*, Yasmina Serinel, Nathaniel S. Marshall, Ronald R. Grunstein

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

30 Citations (Scopus)

Abstract

Excessive daytime sleepiness (EDS) is common in obstructive sleep apnea (OSA), but it is also common in the general population. When sleepiness remains after continuous positive airway pressure (CPAP) treatment of OSA, comorbid conditions or permanent brain injury before CPAP therapy may be the cause of the residual sleepiness. There is currently no broad approach to treating residual EDS in patients with OSA. Individual assessment must be made of comorbid conditions and medications, and of lifestyle factors that may be contributing to the sleepiness. Modafinil and armodafinil are the only pharmacologic agents indicated for residual sleepiness in these patients.

Original languageEnglish
Pages (from-to)353-363
Number of pages11
JournalSleep Medicine Clinics
Volume11
Issue number3
DOIs
Publication statusPublished - 1 Sept 2016
Externally publishedYes

Keywords

  • Armodafinil
  • Comorbid conditions
  • CPAP
  • Excessive daytime sleepiness
  • Modafinil
  • Sleep disorders
  • Wakefulness promoters

Fingerprint

Dive into the research topics of 'Residual daytime sleepiness in obstructive sleep apnea after continuous positive airway pressure optimization: causes and management'. Together they form a unique fingerprint.

Cite this